At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
sunitinib malate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Sunitinib Malate for Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
In Brief
A Phase 2 clinical trial evaluating sunitinib malate, pharmacological study, and 1 other intervention for B-cell Chronic Lymphocytic Leukemia and 2 related conditions. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartAug 2007
Primary CompletionNov 2008
Study CompletionJan 2011
TodayJul 2026
First PostedNov 10, 2006
Enrollment StartAug 1, 2007
Primary CompletionNov 1, 2008
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.6 years ago
Interventions
sunitinib malatedrug
Given orally
pharmacological studyother
Correlative studies
laboratory biomarker analysisother
Correlative studies